Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007787 | 0.92 | ADORA1 (0.52) | MAPK14MAPK13MAPK12MAPK11ADORA1 | |
| SCHEMBL5008532 | 0.87 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11ADORA1 | |
| SCHEMBL5008686 | 0.87 | ADORA1 (0.49) | MAPK14MAPK13MAPK12MAPK11ADORA1 | |
| SCHEMBL4665871 | 0.83 | RAF1 (0.46) | MAPK14MAPK13MAPK12MAPK11ADORA1 | |
| SCHEMBL5007711 | 0.82 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5010696 | 0.82 | ADORA1 (0.54) | MAPK14MAPK13MAPK12MAPK11ADORA1 | |
| SCHEMBL5012222 | 0.81 | ADORA1 (0.62) | MAPK14MAPK13MAPK12MAPK11ADORA1 | |
| SCHEMBL5008388 | 0.80 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11ADORA1 | |
| SCHEMBL5005267 | 0.79 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11GFER | |
| SCHEMBL5008418 | 0.78 | GFER (0.60) | MAPK14MAPK13MAPK12MAPK11ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | MAPK14 1938/4885MAPK13 885/4885MAPK12 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.